Albany Molecular Research (Albany Molecular Research) Long-Term Capital Lease Obligation : $0.0 Mil (As of Jun. 2017)

View and export this data going back to 1999. Start your Free Trial

What is Albany Molecular Research Long-Term Capital Lease Obligation?

Albany Molecular Research's Long-Term Capital Lease Obligation for the quarter that ended in Jun. 2017 was $0.0 Mil.

Albany Molecular Research Long-Term Capital Lease Obligation Historical Data

The historical data trend for Albany Molecular Research's Long-Term Capital Lease Obligation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Albany Molecular Research Long-Term Capital Lease Obligation Chart

Albany Molecular Research Annual Data

Trend

Dec07

Dec08

Dec09

Dec10

Dec11

Dec12

Dec13

Dec14

Dec15

Dec16

Long-Term Capital Lease Obligation

Get a 7-Day Free Trial

Albany Molecular Research Quarterly Data
	Sep12	Dec12	Mar13	Jun13	Sep13	Dec13	Mar14	Jun14	Sep14	Dec14	Mar15	Jun15	Sep15	Dec15	Mar16	Jun16	Sep16	Dec16	Mar17	Jun17
Long-Term Capital Lease Obligation	Get a 7-Day Free Trial															-	-	-	-	-

Albany Molecular Research (NAS:AMRI) Long-Term Capital Lease Obligation Explanation

Long-Term Capital Lease Obligation are the amount due for long-term asset lease agreements that are nearly equivalent to asset purchases. Capital lease obligations are installment payments that constitute a payment of principal plus interest for the capital lease. The Short-Term Capital Lease Obligation is the portion of a Long-Term Capital Lease Obligation that is due over the next year.

Under US Generally Accepted Accounting Principles (GAAP), a capital lease is essentially equivalent to a purchase by the lessee if it meets the following criteria:

1. Ownership of the asset is transferred to the lessee at the end of the lease term;
2. The lease contains a bargain purchase option to buy the equipment at less than fair market value;
3. The lease term equals or exceeds 75% of the asset's estimated useful life;
4. The present value of the lease payments equals or exceeds 90% of the total original cost of the equipment.

Albany Molecular Research Long-Term Capital Lease Obligation Related Terms

Thank you for viewing the detailed overview of Albany Molecular Research's Long-Term Capital Lease Obligation provided by GuruFocus.com. Please click on the following links to see related term pages.

Albany Molecular Research (Albany Molecular Research) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Albany Molecular Research Inc (NAS:AMRI) » Definitions » Long-Term Capital Lease Obligation

Comparable Companies

Traded in Other Exchanges

N/A

Address

Website

http://www.amriglobal.com

Albany Molecular Research provides research services to pharmaceutical, biotechnology, and chemical companies. The company offers services like design and modification of potential lead compounds, purification technique development, quality control, bulk ingredient stability studies, and regulatory documentation preparation. The company has entered into collaborative agreements with companies like Eli Lilly and Cambrex. Albany's acquisition of Organichem provided the company with commercial manufacturing capabilities.

Executives

Anthony J Maddaluna	director	PFIZER INC. ATTN CORPORATE SECRETARY, 235 RAST 42ND STREET, NEW YORK NY 10017
Felicia I Ladin	officer: SVP, Treasurer & CFO	26 CORPORATE CIRCLE, ALBANY NY 12203
David H Deming	director	C/O BETTER FOR YOU WELLNESS, INC., 1349 EAST BROAD ST, COLUMBUS OH 43205
William S Marth	director, officer: President and CEO	236 GROVE STREET, WELLESLEY MA 02482
Lori M. Henderson	officer: SVP, Secretary & Gen Counsel	MOLDFLOW CORP, 430 BOSTON POST ROAD, WAYLAND MA 01778
Una S Ryan	director	329 HAMMOND STREET, CHESTNUT HILL MA 02467
Veronica Gh Jordan	director	C/O ALBANY MOLECULAR RESEARCH, INC., 26 CORPORATE CIRCLE, ALBANY NY 12212-5098
Gabriel Leung	director	C/O PERNIX THERAPEUTICS HOLDINGS, INC., 10 NORTH PARK PLACE, SUITE 201, MORRISTOWN NJ 07960
Michael A Luther	officer: Senior VP, Discovery Services	21 CORPORATE CIRCLE, ALBANY NY 12203
Mark T Frost	officer: Chief Financial Officer	21 CORPORATE CIRCLE, PO BOX 15098, ALBANY NY 12033-5098
David P Waldek	officer: Chief Financial Officer	ALBANY MOLECULAR RESEARCH INC, 21 CORPORATE CIRCLE PO BOX 15098, ALBANY NY 12212-5098

Albany Molecular Research (Albany Molecular Research) Headlines

No Headlines